Drug intelligence / Profile preview

PRO-301

Development stage: Unknown
Lead developer: Proterris
Modality: Small Molecules
Administration: Inhalation

Overview

PRO-301 is an inhaled formulation of carbon monoxide (iCO) being developed by Proterris for the prevention of Delayed Graft Function (DGF) in kidney transplant recipients. The therapeutic approach leverages the cytoprotective, anti-inflammatory, and anti-apoptotic properties of carbon monoxide to mitigate ischemia-reperfusion injury (IRI), which is a primary cause of DGF. By delivering low doses of carbon monoxide via inhalation, the drug aims to activate protective cellular pathways, such as the induction of heme oxygenase-1 (HO-1) and the modulation of mitochondrial function, thereby improving graft survival and function post-transplantation. PRO-301 is currently in Phase 2 development.

Other names: inhaled carbon monoxideiCO

Targets

HMOX1 (Heme oxygenase 1)MEKsGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on PRO-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO-301.

Explore the full profile